AIM
LGND icon

Arcadia Investment Management’s Ligand Pharmaceuticals LGND Stock Holding History

Arcadia Investment Management’s Portfolio LGND Stock Details LGND Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q2 		– Sell
-377
Closed -$25K – 396
2017
Q1 		$25K Buy
+377
New +$24.8K 0.01% 295
2016
Q3 		– Sell
-373
Closed -$28K – 393
2016
Q2 		$28K Buy
+373
New +$27.7K 0.01% 277

Other funds holding LGND

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
William Blair Investment Management
William Blair Investment Management Chicago, Illinois $30.3B AUM 33.75% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
DMK
David M. Knott $275M AUM 59.23% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
CCMLC
Cardinal Capital Management LLC (Connecticut) Greenwich, Connecticut $365M AUM 18.32% 1-Year Est. Return
SCM
Scopia Capital Management New York $146M AUM 25.93% 1-Year Est. Return
Victory Capital Management
Victory Capital Management San Antonio, Texas $156B AUM 27.51% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return

Arcadia Investment Management's LGND Position: Q2 2017 in Review

Arcadia Investment Management sold out of Ligand Pharmaceuticals (LGND) in Q2 2017, closing a stake of 377 shares — an estimated $25K sold.

Arcadia Investment Management first reported a position in LGND in Q2 2016 and held it in 2 quarters. The position peaked at $28K in Q2 2016. 265 funds tracked by Wall St. Rank hold LGND as of Q2 2017.

  • Arcadia Investment Management reported no remaining Ligand Pharmaceuticals position as of Q2 2017 after selling out during the quarter.
  • Arcadia Investment Management sold 377 Ligand Pharmaceuticals shares in Q2 2017, an estimated $25K.
  • Arcadia Investment Management first reported a position in Ligand Pharmaceuticals in Q2 2016 and held it in 2 quarters.
  • Arcadia Investment Management's Ligand Pharmaceuticals position peaked at $28K in Q2 2016.
  • 265 funds tracked by Wall St. Rank held Ligand Pharmaceuticals as of Q2 2017.

Based on Arcadia Investment Management's 13F filing for Q2 2017, filed 3 Aug 2017.